States Ask Supreme Court To Review Pay-To-Delay

January 11, 2011
Pharmalot
By Ed Silverman

The controversy over so-called pay-to-delay settlements between brand-name and generic drugmakers has prompted attorneys general from 32 states to file an amicus, or friend-of-the-court brief urging the US Supreme Court to review the deals, which the states say thwart competition and block needed access to lower-cost medications.

The move comes less than a month after three pharmacy chains and a wholesaler petitioned the court to rule on the issue, which has divided other federal courts and spurred the Federal Trade Commission into a Quixotic quest to urge Congress to pass a law to restrict these deals. Read more

 

 

Also In The News

Tell Us Your Thoughts

How do you feel about having to pay more than everyone else for your medication? Tell us your story. **By filling out this form you are giving RxRights permission to use your comments to help build support for safe, affordable drug importation.**